- Adjuvant targeted therapy was tied to significantly decreased OS in patients with high-risk locoregional renal cancer carcinoma (RCC) who underwent partial or radical nephrectomy.
- pN+ patients had worse survival with adjuvant therapy.
Why this matters
- Clinical trials did not capture OS decline with adjuvant targeted therapy reported in current real-world analysis.
- Study of 41,127 patients with high-risk nonmetastatic clear cell RCC who underwent nephrectomy during 2006-2015.
- Adjuvant therapy was defined as chemotherapy received within 3 months of surgery.
- Primary outcome: OS.
- Funding: None disclosed.
- 5.04% of patients received adjuvant targeted therapy.
- Significant risk factors for off-label adjuvant targeted therapy use:
- pT4 (OR, 2.85; P<.001>
- pN+ (OR, 3.49; P<.001>
- Retrospective design.